Tourmaline Bio Inc
NASDAQ:TRML

Watchlist Manager
Tourmaline Bio Inc Logo
Tourmaline Bio Inc
NASDAQ:TRML
Watchlist
Price: 47.98 USD
Market Cap: 1.2B USD

Relative Value

There is not enough data to reliably calculate the relative value of TRML.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TRML Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-5.6
Industry
23.7
Forward
-12.7
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-5.4
Industry
22
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-5.4
Industry
23.8
vs History
0
vs Industry
49
Median 3Y
1.3
Median 5Y
1
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-0.2
Industry
6.4
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-0.2
Industry
7
Forward
-10
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-0.2
Industry
8.3
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-0.2
Industry
6.5
vs History
8
vs Industry
33
Median 3Y
2.8
Median 5Y
0.8
Industry
5.7

Multiples Across Competitors

TRML Competitors Multiples
Tourmaline Bio Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Tourmaline Bio Inc
NASDAQ:TRML
1.2B USD 0 -14.2 -10.2 -10.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 809 907.8 -160 693.5 -195 133.1 -192 906.4
US
Abbvie Inc
NYSE:ABBV
400.4B USD 6.7 170.6 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
173.6B USD 4.8 24.7 17.9 17.9
US
Gilead Sciences Inc
NASDAQ:GILD
151.3B USD 5.2 18.7 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115B USD 9.8 31.3 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 083.7 -531.7 -579 -563.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.5B USD 5.6 17.4 16.5 18.8
AU
CSL Ltd
ASX:CSL
86.8B AUD 3.7 19.2 12.9 16.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.4 1 213.7 158 191.6
NL
argenx SE
XBRU:ARGX
43.8B EUR 14.1 33.1 57.8 59.4
P/S Multiple
Revenue Growth P/S to Growth
US
Tourmaline Bio Inc
NASDAQ:TRML
Average P/S: 3 381 205.8
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 809 907.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 083.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
NL
argenx SE
XBRU:ARGX
14.1
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Tourmaline Bio Inc
NASDAQ:TRML
Average P/E: 191.1
Negative Multiple: -14.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 693.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.7
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.7
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.3
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
9%
1.9
AU
CSL Ltd
ASX:CSL
19.2
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 213.7
N/A N/A
NL
argenx SE
XBRU:ARGX
33.1
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Tourmaline Bio Inc
NASDAQ:TRML
Average EV/EBITDA: 39.4
Negative Multiple: -10.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 133.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.9
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.9
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158
N/A N/A
NL
argenx SE
XBRU:ARGX
57.8
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Tourmaline Bio Inc
NASDAQ:TRML
Average EV/EBIT: 45.5
Negative Multiple: -10.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 906.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.9
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
13%
1.4
AU
CSL Ltd
ASX:CSL
16.1
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.6
N/A N/A
NL
argenx SE
XBRU:ARGX
59.4
N/A N/A